Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Farnesylacetate, Geranyl
2. Gefarnil
3. Gepharnate
4. Geranyl Farnesylacetate
5. Ulco
1. 51-77-4
2. Geranyl Farnesylacetate
3. Gefanil
4. 3,7-dimethylocta-2,6-dien-1-yl 5,9,13-trimethyltetradeca-4,8,12-trienoate
5. Da-688
6. [(2e)-3,7-dimethylocta-2,6-dienyl] (4e,8e)-5,9,13-trimethyltetradeca-4,8,12-trienoate
7. Da 688
8. 1ise2y6ula
9. Gefarnyl
10. Ncgc00182546-01
11. Gefarnil
12. Trans-3,7-dimethyl-2,6-octadienyl 5,9,13-trimethyl-4,8,12-tetradecatrienoate
13. Dsstox_cid_28562
14. Dsstox_rid_82834
15. Dsstox_gsid_48636
16. Gefarnatum
17. Gefarnato
18. Gefarnatum [inn-latin]
19. Gefarnato [inn-spanish]
20. 5,9,13-trimethyl-4,8,12-tetradecatrienoic Acid 3,7-dimethyl-2,6-octadienyl Ester
21. Cas-51-77-4
22. Gefarnate [inn:ban:jan]
23. 4,8,12-tetradecatrienoic Acid, 5,9,13-trimethyl-, (2e)-3,7-dimethyl-2,6-octadienyl Ester, (4e,8e)-
24. Einecs 200-121-0
25. Unii-1ise2y6ula
26. Osteol
27. Geranyl-farnesylacetate
28. Gefarnate [inn]
29. Gefarnate [jan]
30. Gefarnate [mi]
31. Gefarnate [mart.]
32. Gefarnate [who-dd]
33. (e,e,e)-5,9,13-trimethyl-4,8,12-tetradecatrienoic Acid 3,7-dimethyl-2,6-octadienyl Ester
34. Schembl148495
35. 3,7-dimethylocta-2,6-dienyl 5,9,13-trimethyltetradeca-4,8,12-trienoate
36. Chembl2105085
37. Dtxsid0048636
38. Chebi:31646
39. Hy-b2206
40. Zinc3872668
41. Tox21_112983
42. Mfcd00129086
43. Nsc138947
44. S5477
45. Akos015966756
46. Tox21_112983_1
47. Ac-2134
48. Ccg-268656
49. Cs-7652
50. Db12079
51. Nsc-138947
52. Ncgc00182546-02
53. 111ge003
54. 4,8,12-tetradecatrienoic Acid, 5,9,13-trimethyl-, 3,7-dimethyl-2,6-octadienyl Ester, (e,e,e)-
55. As-15887
56. C75428
57. 051g774
58. Q5530013
59. (4e,8e)-(e)-3,7-dimethylocta-2,6-dien-1-yl 5,9,13-trimethyltetradeca-4,8,12-trienoate
60. 4,8,12-tetradecatrienoic Acid, 5,9,13-trimethyl-, (2e)-3,7-dimethyl-2,6-octadien-1-yl Ester, (4e,8e)-
Molecular Weight | 400.6 g/mol |
---|---|
Molecular Formula | C27H44O2 |
XLogP3 | 9.1 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 15 |
Exact Mass | 400.334130642 g/mol |
Monoisotopic Mass | 400.334130642 g/mol |
Topological Polar Surface Area | 26.3 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 619 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 3 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Anti-Ulcer Agents
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)
A - Alimentary tract and metabolism
A02 - Drugs for acid related disorders
A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
A02BX - Other drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
A02BX07 - Gefarnate
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Gefarnate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Gefarnate, including repackagers and relabelers. The FDA regulates Gefarnate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Gefarnate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Gefarnate supplier is an individual or a company that provides Gefarnate active pharmaceutical ingredient (API) or Gefarnate finished formulations upon request. The Gefarnate suppliers may include Gefarnate API manufacturers, exporters, distributors and traders.
Gefarnate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Gefarnate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Gefarnate GMP manufacturer or Gefarnate GMP API supplier for your needs.
A Gefarnate CoA (Certificate of Analysis) is a formal document that attests to Gefarnate's compliance with Gefarnate specifications and serves as a tool for batch-level quality control.
Gefarnate CoA mostly includes findings from lab analyses of a specific batch. For each Gefarnate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Gefarnate may be tested according to a variety of international standards, such as European Pharmacopoeia (Gefarnate EP), Gefarnate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Gefarnate USP).
LOOKING FOR A SUPPLIER?